So far in 2025, the year’s biggest cultural events have served as launchpads for several of the industry's latest cancer ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Finding stocks with the potential to double in just three years is no easy feat, even in this bull market. Plenty of ...

A few notable health care deals along with M&A in the AI-adjacent and reshoring themes occurred in January. Read more here.

Philanthropy helped build artificial intelligence as a nonprofit research field. But as costs soar and corporations take over ...

As Valentine's Day approaches, the UConn School of Pharmacy wants to celebrate the chemistry we find in and out of our ...

S&P 500 E-Mini futures (ESH25) are up +0.20%, andMarch Nasdaq 100 E-Mini futures (NQH25) are up +0.10% this morning, ...

Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of off-the-shelf neuron replacement therapies for neurological ...

By capitalizing on its advantages for business of all sizes, Wisconsin is seeing significant growth in legacy and emerging ...

GLP-1 drugs Mounjaro and Zepbound drive a big revenue increase for the drugmaker Eli Lilly & Co. said Thursday ... visit our privacy center. Maintaining independence and editorial freedom is ...

Lilly on Thursday reported fourth-quarter revenue of $13.53 billion, a steep 45% increase over the sum the Indianapolis-based drugmaker generated during the same period in 2023.